Signal
Less than two weeks after rejecting sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the complete response letter, citing both effi
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-01-07 10:47 UTCUpdated 2026-01-07 10:47 UTC
rss
fierce_pharma
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the complete response letter, citing both efficacy and safety concerns, including a case of serious liver injury that led to death.
Score total
0.7
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
50%
All evidence
All evidence
Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the complete response letter, citing both efficacy and safety c...
Fierce Biotech (All) · fiercebiotech.com · 2026-01-07 10:47 UTC
Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the complete response letter, citing both efficacy and safety c...
Fierce Pharma (All) · fiercepharma.com · 2026-01-07 10:47 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Biotech (All) (1)
- Fierce Pharma (All) (1)
Top origin domains (this list)
- fiercebiotech.com (1)
- fiercepharma.com (1)